Gabather AB (publ) (GABA.ST)
- Previous Close
0.0448 - Open
0.0458 - Bid 0.0420 x --
- Ask 0.0476 x --
- Day's Range
0.0456 - 0.0476 - 52 Week Range
0.0266 - 2.5000 - Volume
151,800 - Avg. Volume
681,158 - Market Cap (intraday)
11.243M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
www.gabather.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GABA.ST
View MorePerformance Overview: GABA.ST
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GABA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GABA.ST
View MoreValuation Measures
Market Cap
10.11M
Enterprise Value
9.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-105.67%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.75M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
878k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.86M